Market Place
Sourcing Support
Australia`s Noxopharm scales up production of lupus medication
18 May 2024 //
BIOSPECTRUM ASIA
Australia`s Noxopharm receives A$1.45M grant for inflammation-based research
27 Jun 2022 //
BIOSPECTRUMASIA
FDA Grants Orphan Drug Designation to Noxopharm for Sarcoma Treatment
29 Mar 2022 //
BUSINESSWIRE
Sarcoma Trial for New Cancer Treatment Begins at City of Hope in Los Angeles
08 Mar 2022 //
PRESS RELEASE
Here’s why the Noxopharm (ASX: NOX) share price leapt 7% today
13 Dec 2021 //
FOOL
Noxopharm In-Licenses Novel RNA Technology From HIMR
01 Dec 2021 //
BUSINESSWIRE
Noxopharm Announces DARRT-2 Clinical Trial in U.S.
09 Nov 2021 //
BUSINESSWIRE
Noxopharm clinical trial reveals anti-inflammatory response in COVID-19 patients
25 Aug 2021 //
BUSINESSWIRE
Noxopharm Confirms Advantage of Combination LuPSMA Therapy in Prostate Cancer
12 Aug 2021 //
BUSINESSWIRE
Noxopharm & U.S. National Cancer Institute to Collaborate
09 Aug 2021 //
PROACTIVEINVESTORS
Noxopharm’s (ASX:NOX) DARRT-2 study gets green light from FDA
01 Jul 2021 //
MARKET HERALD
Clinical study shows drug has COVID-19 treatment potential
13 May 2021 //
OUTSOURCING-PHARMA
Noxopharm’s Veyonda to Begin First-Line Sarcoma Treatment Testing
11 May 2021 //
BIOSPACE
Noxopharm will progress to FDA approved breakthrough testing of Veyonda
07 May 2021 //
PROACTIVEINVESTOR
Clinical Data Shows Noxopharm’s Veyonda® May Prevent Cytokine Storm
27 Apr 2021 //
BUSINESSWIRE
Clinical Data Shows Noxopharm’s Veyonda® May Prevent Cytokine Storm
27 Apr 2021 //
BUSINESSWIRE
Noxopharm Files Septic Shock Treatment Patent for Veyonda®
14 Apr 2021 //
BIOSPACE
Noxopharm`s NOXCOVID trial moves to final phase
18 Mar 2021 //
BUSINESSWIRE
Prostate cancer drug demonstrates major survival benefit
02 Mar 2021 //
OUTSOURCING-PHARMA
Independent Discovery Validates Noxopharm’s DARRT Cancer Therapy
04 Dec 2020 //
BUSINESSWIRE
Noxopharm Announces First COVID-19 Patient Treated in Veyonda® Study
08 Oct 2020 //
BUSINESSWIRE
Noxopharm Announces New Research Showing Veyonda® Cancer Survival Rates
18 Aug 2020 //
PRESS RELEASE
Noxopharm Reports Idronoxil Achieves Major Industry Goal of Converting ‘Cold’
23 Jul 2020 //
PRESS RELEASE
Noxopharm launches Phase I COVID-19 program in Europe
02 Jul 2020 //
OUTSOURCING
Noxopharm Reports COVID-19 Trial Program to Commence in Europe
25 Jun 2020 //
BUSINESSWIRE
Noxopharm Reports Veyonda’s Potential in Late-Stage Cancer at ASCO 2020
04 Jun 2020 //
BUSINESSWIRE
Noxopharm reports positive results for prostate cancer drug
26 May 2020 //
OUTSOURCING-PHARMA
Noxopharm Achieves Abscopal Responses in Prostate Cancer
06 May 2020 //
BUSINESSWIRE
Noxopharm Investigating Potential COVID-19 Treatment
02 Apr 2020 //
PRESS RELEASE
Noxopharm Investigating Potential COVID-19 Treatment
02 Apr 2020 //
PRESS RELEASE
US FDA approves Noxopharm’s Veyonda in combo with doxorubicin
27 Feb 2020 //
PHARMABIZ
FDA Grants IND Approval to Promising Anti-Cancer Agent Veyonda®
25 Feb 2020 //
PRESS RELEASE
BRIEF-Noxopharm Says U.S. FDA Grants IND Approval To Veyonda
21 Feb 2020 //
FINNEWSNETWORK
LuPIN Trial Interim Results Indicate Striking Survival Benefit
14 Feb 2020 //
PRESS RELEASE
Noxopharm to transform cancer treatment space
28 Jan 2020 //
BIOSPECTRUMASIA
